MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome that has become a focal point for researchers studying how mitochondria signal to the rest of the cell. This article surveys what the experimental literature actually reports about MOTS-c and glucose homeostasis across cell, rodent and human-cohort studies, and where that evidence remains preliminary or contested.

What is MOTS-c?

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) was first described in 2015 by Lee and colleagues, who identified a short open reading frame within the mitochondrial 12S ribosomal RNA gene that encodes a 16-amino-acid peptide.¹ The finding extended an emerging concept: that the small, semi-autonomous mitochondrial genome does not merely encode components of the respiratory chain but also produces bioactive signalling peptides. MOTS-c belongs to a broader family of mitochondrial-derived peptides (MDPs) that also includes humanin and the six small humanin-like peptides, each translated from short open reading frames embedded in mitochondrial ribosomal RNA genes.⁶

Two features make MOTS-c of particular interest to metabolic researchers. First, it functions as a systemic signal rather than a purely local one: the peptide is detectable in circulation and can translocate to the nucleus under metabolic stress, where it has been associated with the regulation of stress-adaptive and antioxidant-response gene networks.⁷ Second, in the original characterisation its primary experimental target organ appeared to be skeletal muscle, positioning MOTS-c within the same physiological neighbourhood as classical regulators of glucose disposal.¹ Because researchers frequently pair mitochondrial peptides with cofactor substrates in study designs, materials such as NAD+ are sometimes examined alongside MOTS-c in the same experimental context, though the two are mechanistically distinct.

The core mechanism: folate cycle, AICAR and AMPK

The mechanistic model that dominates the MOTS-c literature was proposed in the founding study and refined by subsequent reviews. In cultured cells, MOTS-c was reported to inhibit the folate cycle and its tethered de novo purine biosynthesis pathway. The resulting accumulation of the intermediate 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) — an endogenous AMP mimetic — is proposed to activate AMP-activated protein kinase (AMPK), a central cellular energy sensor.¹ This is why MOTS-c is often described mechanistically through a “Folate–AICAR–AMPK” axis in the review literature.⁷

Downstream of AMPK activation, experimental models describe increased glucose transporter (GLUT4) trafficking to the plasma membrane in muscle and adipose cells, a step that would in principle enhance insulin-independent glucose uptake.⁸ Mechanistic reviews have also linked MOTS-c activity to changes in the expression of genes such as GLUT4, STAT3 and IL-10, consistent with a role that extends from acute metabolic signalling to longer-term transcriptional adaptation.⁸

Nuclear translocation under stress

A distinguishing observation is that MOTS-c does not remain confined to the cytoplasm. Under metabolic stress — glucose restriction, oxidative challenge or exercise — MOTS-c has been reported to translocate into the nucleus, where it associates with stress-responsive transcription factors and antioxidant response elements (ARE), influencing the expression of adaptation-related genes.⁷ This retrograde signalling, from mitochondrion to nucleus, is the basis for describing MOTS-c as a mitochondrial-encoded regulator rather than a simple metabolic hormone.²

A peripheral, not hepatic, emphasis

An important nuance for interpreting the diabetes literature is that MOTS-c, in the preclinical studies to date, is not characterised as a direct suppressor of hepatic gluconeogenesis in the manner of metformin. Instead, its reported effects on glucose handling are attributed predominantly to peripheral tissues — skeletal muscle and adipose — via AMPK-linked pathways.¹ Whether AMPK is strictly required for every reported MOTS-c effect remains an active question; some adipose studies have used AMPK inhibitors to show attenuation of the peptide's activity, supporting a causal role in those settings.⁹

Diet-induced obesity and insulin resistance in rodents

The most reproducible MOTS-c observations come from rodent models of dietary overload. In the founding study, MOTS-c administration to mice was reported to attenuate high-fat-diet-induced insulin resistance and diet-induced obesity, while normal-diet control animals remained metabolically unchanged — a pattern suggesting a context-dependent effect that emerges under metabolic stress rather than a generalised action.¹ Hyperinsulinemic-euglycemic clamp analyses in that work pointed to skeletal muscle as the tissue where glucose routing was preferentially affected.¹

Subsequent studies have extended the model into other forms of metabolic stress. In an ovariectomy model of post-menopausal metabolic dysfunction, MOTS-c treatment was associated with reduced fat accumulation, increased brown adipose activation and improved insulin sensitivity, effects that were attenuated when the AMPK pathway was blocked.⁹ Separately, MOTS-c has been reported to reduce myostatin expression and muscle-atrophy signalling in diet-induced obese mice, acting through an AKT–FOXO1 axis; notably, that same study reported an inverse correlation between circulating MOTS-c and myostatin in human subjects, linking the rodent mechanism to a measurable human association.¹⁰

Several mechanistic observations recur across these obesity models:

• Increased skeletal-muscle glucose disposal specifically under high-fat dietary conditions, with limited effect on normally fed controls.¹
• Attenuation of hyperinsulinemia and reduced peripheral fat accumulation in treated animals.¹
• Enhanced brown adipose tissue activity and energy dissipation in the ovariectomy model.⁹
• Reduced atrophy-related transcription via AKT-mediated inhibition of FOXO1.¹⁰

It is worth stressing that these are preclinical, largely rodent findings. They describe what happens in controlled animal systems and do not establish outcomes in humans.

Aging, exercise and endogenous MOTS-c

A second major research theme connects MOTS-c to aging and physical activity. In the founding study, MOTS-c administration attenuated age-dependent insulin resistance in older mice, with a seven-day treatment period reported to improve insulin-stimulated glucose handling in soleus muscle without changes in body weight, alongside increased AMPK and AKT signalling.¹ This positioned the peptide as a candidate node linking mitochondrial function to the metabolic decline associated with aging.

The link to exercise was strengthened by a 2021 study reporting that MOTS-c is an exercise-induced, mitochondrial-encoded regulator of age-dependent physical decline. In that work, MOTS-c treatment enhanced physical performance in young, middle-aged and old mice, and regulated nuclear genes related to metabolism and proteostasis. Critically, the authors reported that in humans, exercise itself induces endogenous MOTS-c expression in skeletal muscle and in circulation — an observation that frames MOTS-c as part of the body's own adaptive response to physical stress rather than a purely exogenous agent.²

Review analyses of mitochondrial-derived peptides in energy metabolism have summarised this bidirectional pattern: circulating MDPs, including MOTS-c, tend to be lower in states such as obesity, diabetes and aging, whereas muscle expression can be acutely upregulated by stressors that perturb mitochondria, including exercise.⁶ The interpretation offered is that MOTS-c forms part of a retrograde signalling network communicating mitochondrial status to the wider organism — a hypothesis that remains under investigation rather than an established fact.

Human cohort evidence — and why it is contested

Human data on MOTS-c are entirely observational and, importantly, inconsistent. This section deserves careful reading because the popular framing of MOTS-c often overstates the coherence of the human evidence.

On one side, a case-control study in Chinese children and adolescents reported that circulating MOTS-c was significantly lower in obese male participants than in controls, and that MOTS-c levels correlated negatively with body mass index, waist circumference, fasting insulin, HOMA-IR and HbA1c in the male cohort. In female participants, no significant difference was observed.³ This sex-specific pattern is a recurring and unexplained feature of the MOTS-c literature.

A 2024 systematic review and meta-analysis of seven studies (602 participants) attempted to reconcile the findings. Its pooled result was that circulating MOTS-c was significantly reduced in diabetes but, in a subgroup analysis, significantly increased in obesity once overweight (rather than frankly obese) individuals were excluded.⁴ In other words, the direction of the association appears to differ between diabetes and obesity, undercutting any single narrative in which “low MOTS-c” uniformly marks metabolic disease.

A further complication comes from a study in lean and obese adults that found no significant difference in plasma MOTS-c concentration between the two groups; the correlations with insulin-sensitivity indices held mainly in lean individuals and appeared altered once obesity was established.⁵ Taken together, the human literature supports the idea that MOTS-c is metabolically informative but does not yet define a consistent, causal biomarker relationship.

Diabetes and cardiometabolic models

Beyond obesity, MOTS-c has been examined in models specifically framed around diabetes and its complications. Mechanistic reviews position GLUT4-dependent glucose uptake as central to insulin sensitivity and glucose tolerance, and it is through this transporter that AMPK-linked signals are proposed to influence glucose handling in diabetes-relevant systems.⁸

Genetic evidence: the K14Q polymorphism

Some of the most compelling human-relevant evidence is genetic rather than interventional. An Asian-specific mitochondrial DNA variant (m.1382A>C) produces a K14Q amino-acid substitution in MOTS-c. In a meta-analysis of three cohorts totalling more than 27,000 individuals, males carrying the C-allele showed a higher prevalence of type 2 diabetes, and the risk was concentrated in physically inactive men — a gene-by-lifestyle interaction the authors termed “kinesio-genomic.” In parallel mouse experiments, wild-type MOTS-c improved glucose tolerance while the K14Q variant did not, and, mirroring the human data, female mice were unaffected.¹¹ This convergence of human genetics and rodent function is a notable strength, though it again highlights the unexplained sex specificity.

Cardiac complications

In a streptozotocin-induced type 1 diabetes model, twelve weeks of subcutaneous MOTS-c administration was reported to attenuate diabetic cardiomyopathy, with improved cardiac function and structure, restored AMPK signalling and reduced myocardial inflammation.¹² The authors themselves frame these as therapeutic-potential findings warranting further investigation — that is, hypothesis-generating preclinical results, not clinical evidence.

Exercise synergy

Because endogenous MOTS-c is induced by exercise, several research designs have examined the peptide alongside physical training. The consistent theme across reviews is that MOTS-c and exercise appear to engage overlapping AMPK- and mitochondrial-biogenesis pathways, which is one reason the peptide is frequently described as an “exercise-mimetic” signal in mechanistic discussions.² This label is a research shorthand for shared signalling, not a claim about outcomes in people.

Research considerations and limitations

For laboratories designing MOTS-c studies, several features of the literature shape interpretation. The peptide is short (16 residues) and its measured circulating concentrations vary widely between assays and cohorts, which is part of why human correlation studies disagree.⁴ The dominant readouts in mechanistic work — AMPK phosphorylation, GLUT4 translocation, glucose uptake in cultured muscle cells, and clamp-based disposal in rodents — are well established, but the field still lacks large, prospective human interventional data.

Common experimental systems include cultured skeletal-muscle cells (such as C2C12 myotubes), adipocytes, and rodent high-fat-diet or genetic models. Reported effects are frequently context-dependent, appearing under metabolic stress and being minimal in metabolically normal controls, so control-condition design matters.¹ The sex-specific findings in both human cohorts and mouse genetics¹¹ argue for sex as a pre-registered variable rather than an afterthought. Materials such as MOTS-c used in these settings are laboratory reagents whose characterisation — identity, purity and batch consistency — directly affects reproducibility.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.